Andy Hsieh
Stock Analyst at William Blair
(2.44)
# 3,065
Out of 5,118 analysts
361
Total ratings
40.8%
Success rate
0.9%
Average return
Main Sectors:
Stocks Rated by Andy Hsieh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ELVN Enliven Therapeutics | Reiterated: Buy | n/a | $49.43 | - | 3 | Oct 6, 2026 | |
| NKTR Nektar Therapeutics | Reiterated: Buy | n/a | $37.26 | - | 32 | Oct 1, 2026 | |
| KLRA Kailera Therapeutics | Reiterated: Buy | n/a | $12.97 | - | 6 | Sep 30, 2026 | |
| TLX Telix Pharmaceuticals | Reiterated: Buy | n/a | $9.63 | - | 1 | Sep 22, 2026 | |
| VKTX Viking Therapeutics | Reiterated: Buy | n/a | $26.84 | - | 40 | Sep 22, 2026 | |
| CATX Perspective Therapeutics | Initiated Coverage: Buy | n/a | $0.84 | - | 1 | Sep 18, 2026 | |
| CRBP Corbus Pharmaceuticals Holdings | Reiterated: Buy | n/a | $3.07 | - | 17 | Sep 14, 2026 | |
| CRDF Cardiff Oncology | Reiterated: Hold | n/a | $0.7953 | - | 19 | Sep 14, 2026 | |
| EXEL Exelixis | Reiterated: Buy | n/a | $69.57 | - | 60 | Sep 11, 2026 | |
| PYXS Pyxis Oncology | Reiterated: Hold | n/a | $1.66 | - | 12 | Sep 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $20.35 | - | 12 | Sep 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $3.73 | - | 29 | Aug 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $1.17 | - | 6 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $2.08 | - | 12 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $4.31 | - | 11 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $100.61 | - | 18 | Aug 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $5.34 | - | 14 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $0.3602 | - | 5 | Jul 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $0.9903 | - | 17 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | - | n/a | 8 | Jul 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.43 | n/a | 15 | Dec 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.626 | n/a | 22 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $166.89 | n/a | 1 | Feb 12, 2019 |
Enliven Therapeutics
Oct 6, 2026
Reiterated: Buy
Price Target: n/a
Current: $49.43
Upside: -
Nektar Therapeutics
Oct 1, 2026
Reiterated: Buy
Price Target: n/a
Current: $37.26
Upside: -
Kailera Therapeutics
Sep 30, 2026
Reiterated: Buy
Price Target: n/a
Current: $12.97
Upside: -
Telix Pharmaceuticals
Sep 22, 2026
Reiterated: Buy
Price Target: n/a
Current: $9.63
Upside: -
Viking Therapeutics
Sep 22, 2026
Reiterated: Buy
Price Target: n/a
Current: $26.84
Upside: -
Perspective Therapeutics
Sep 18, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $0.84
Upside: -
Corbus Pharmaceuticals Holdings
Sep 14, 2026
Reiterated: Buy
Price Target: n/a
Current: $3.07
Upside: -
Cardiff Oncology
Sep 14, 2026
Reiterated: Hold
Price Target: n/a
Current: $0.7953
Upside: -
Exelixis
Sep 11, 2026
Reiterated: Buy
Price Target: n/a
Current: $69.57
Upside: -
Pyxis Oncology
Sep 9, 2026
Reiterated: Hold
Price Target: n/a
Current: $1.66
Upside: -
Sep 8, 2026
Reiterated: Buy
Price Target: n/a
Current: $20.35
Upside: -
Aug 31, 2026
Reiterated: Hold
Price Target: n/a
Current: $3.73
Upside: -
Aug 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $1.17
Upside: -
Aug 12, 2026
Reiterated: Hold
Price Target: n/a
Current: $2.08
Upside: -
Aug 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $4.31
Upside: -
Aug 8, 2026
Reiterated: Hold
Price Target: n/a
Current: $100.61
Upside: -
Aug 6, 2026
Reiterated: Hold
Price Target: n/a
Current: $5.34
Upside: -
Jul 29, 2026
Reiterated: Buy
Price Target: n/a
Current: $0.3602
Upside: -
May 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $0.9903
Upside: -
Jul 23, 2025
Rated: Hold
Price Target: n/a
Current: -
Upside: n/a
Dec 22, 2023
Rated: Hold
Price Target: n/a
Current: $1.43
Upside: n/a
Dec 1, 2021
Downgraded: Hold
Price Target: n/a
Current: $0.626
Upside: n/a
Feb 12, 2019
Reiterated: Buy
Price Target: n/a
Current: $166.89
Upside: n/a